Elisa Chiadini

Impact of <i>TP53</i> Mutations on Outcome in <i>EGFR</i> -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Matteo Canale, Elisabetta Petracci, Angelo Delmonte et al. · Clinical Cancer Research · 2016 · 297 citations · Full text

Medicine, Oncology, Pharmacology +16

Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs

Francesco� Fabbri, Silvia Carloni, Wainer Zoli et al. · Cancer Letters · 2013 · 220 citations

Medicine, Biomedical Engineering, Oncology +17

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy

Paola Ulivi, Elisa Chiadini, Claudio Dazzi et al. · Clinical Lung Cancer · 2015 · 89 citations

Medicine, Molecular Genetics, Oncology +14

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs

Matteo Canale, Elisabetta Petracci, Angelo Delmonte et al. · Journal of Clinical Medicine · 2020 · 70 citations · Full text

Medicine, Oncology, Pharmacology +16

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study

Paola Ulivi, Laura Capelli, Martina Valgiusti et al. · Journal of Translational Medicine · 2012 · 43 citations · Full text

Medicine, Molecular Genetics, Oncology +17